Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy

Genetics and Molecular Research - Brazil
doi 10.4238/2015.december.7.3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Genetics and Molecular Research

Related search

P53 Expression Status Is Associated With Cancer-Specific Survival in Stage III and High-Risk Stage II Colorectal Cancer Patients Treated With Oxaliplatin-Based Adjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2019English

Association of Thymidylate Synthase Expression and Clinical Outcomes of Gastric Cancer Patients Treated With Fluoropyrimidine-Based Chemotherapy: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2016English

Outcomes of Advanced Gastric Cancer in Young Adult Patients Treated With First-Line Combination Chemotherapy

International Journal of Cancer Therapy and Oncology
2015English

GOLPH3 Predicts Survival of Colorectal Cancer Patients Treated With 5-Fluorouracil-Based Adjuvant Chemotherapy

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

ERCC1 mRNA Expression Is Associated With the Clinical Outcome of Non-Small Cell Lung Cancer Treated With Platinum-Based Chemotherapy

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2014English

ERCC1 Codon 118 Polymorphism Is a Useful Prognostic Marker in Patients With Pancreatic Cancer Treated With Platinum-Based Chemotherapy

International Journal of Oncology
Cancer ResearchOncology
2008English

Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer

JAMA - Journal of the American Medical Association
Medicine
2013English

A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2012English

Excision Repair Cross-Complementing Group-1 (ERCC1) Induction Kinetics and Polymorphism Are Markers of Inferior Outcome in Patients With Colorectal Cancer Treated With Oxaliplatin

Oncotarget
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy